An open-label, single-arm, multicenter, prospective clinical study of Hanlikang and BTK inhibitors in the treatment of newly diagnosed mantle cell lymphoma
Age 18-70, ECOG score 0-2;
Estimated survival time >6 months;
Mantle cell lymphoma was confirmed by pathology.
Acceptable hematological indexes without chemotherapy contraindications; Neutrophil absolute value ≥1.0×10^9 /L, PLT≥75×10^9 /L, hemoglobin ≥80g/L (except patients with lymphoma bone marrow infiltration);
Patients with definite neuropathy or psychosis, including dementia or seizures, a history of psychotropic substance abuse and inability to abstinence, or other substantial lesions that may increase CNS toxicity;
Participating in other clinical trials or participating in other clinical investigators 4 weeks before enrollment (except those not receiving treatment);
Systemic autoimmune disease or immune deficiency;
Refusing to collect blood samples;